Point72 Asset Management
KPTI icon

Point72 Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Point72 Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18
Closed -$364 – 2487
2023
Q3 		$364 Buy
+18
New +$404 ﹤0.01% 2378
2023
Q1 		– Sell
-132,774
Closed -$6.77M – 2404
2022
Q4 		$6.77M Buy
132,774
+132,541
+56,885% +$9.19M 0.02% 667
2022
Q3 		$19K Buy
+233
New +$17.4K ﹤0.01% 1329
2020
Q4 		– Sell
-23,315
Closed -$5.11M – 1030
2020
Q3 		$5.11M Buy
+23,315
New +$5.7M 0.03% 552
2019
Q3 		– Sell
-173,088
Closed -$15.6M – 1321
2019
Q2 		$15.6M Buy
+173,088
New +$13.9M 0.08% 301
2019
Q1 		– Sell
-102,781
Closed -$14.4M – 1124
2018
Q4 		$14.4M Buy
102,781
+46,081
+81% +$7.77M 0.07% 331
2018
Q3 		$14.5M Sell
56,700
-39,446
-41% -$10.9M 0.06% 379
2018
Q2 		$24.5M Sell
96,146
-34,422
-26% -$8.51M 0.1% 253
2018
Q1 		$26.3M Sell
130,568
-92,898
-42% -$18.5M 0.11% 240
2017
Q4 		$32.2M Buy
+223,466
New +$35.9M 0.14% 198
2014
Q4 		– Sell
-2,627
Closed -$1.38M – 748
2014
Q3 		$1.38M Buy
2,627
+2,094
+393% +$1.18M 0.01% 528
2014
Q2 		$372K Buy
+533
New +$248K ﹤0.01% 649

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Point72 Asset Management's KPTI Position: Q4 2023 in Review

Point72 Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 18 shares — an estimated $364 sold.

Point72 Asset Management first reported a position in KPTI in Q2 2014 and held it in 12 quarters. The position peaked at $32.2M in Q4 2017. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • Point72 Asset Management reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 18 Karyopharm Therapeutics shares in Q4 2023, an estimated $364.
  • Point72 Asset Management first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 12 quarters.
  • Point72 Asset Management's Karyopharm Therapeutics position peaked at $32.2M in Q4 2017.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.